Literature DB >> 10192675

Feasibility of an emergency department-based tuberculosis counseling and screening program.

T D Kirsch1, A Chanmugam, P Keyl, L A Regan, J Shahan, D A Hexter, G D Kelen.   

Abstract

OBJECTIVE: To assess the feasibility and effectiveness of an ED-based tuberculosis (TB) screening program.
METHODS: A TB screening program of adult ED patients was conducted at a university hospital ED with 46,000 annual visits that serves a poor urban community. Patients were screened on weekdays during business hours. ED patients were counseled about the disease and the screening procedure and, after consent, purified protein derivative (PPD) tests were placed. Patients returned in 48-72 hours for reaction reading and post-test counseling. PPD-positive patients received a physical examination, chest x-ray, and HIV testing and were referred to a city TB clinic for possible treatment.
RESULTS: Overall, 873 patients were counseled, 630 were eligible for screening, and 374 (59.4%) consented to PPD testing. Of the 203 (54.1%) who returned, 32 (15.8%) were PPD-positive. No active case was detected, but 26 patients were referred to the health department. Eighteen kept their appointments and all 13 who were started on therapy completed treatment. Targeted screening of groups aged 55 years or more, nonwhite groups, and those with other high-risk factors would detect 84% of PPD-positive cases while testing only 48% of eligible patients.
CONCLUSION: An ED-based TB screening program is feasible and can identify many patients requiring treatment. Targeted screening of high-risk groups could reduce the program cost, but would miss some cases.

Entities:  

Mesh:

Year:  1999        PMID: 10192675     DOI: 10.1111/j.1553-2712.1999.tb00161.x

Source DB:  PubMed          Journal:  Acad Emerg Med        ISSN: 1069-6563            Impact factor:   3.451


  6 in total

1.  The efficacy and value of emergency medicine: a supportive literature review.

Authors:  C James Holliman; Terrence M Mulligan; Robert E Suter; Peter Cameron; Lee Wallis; Philip D Anderson; Kathleen Clem
Journal:  Int J Emerg Med       Date:  2011-07-22

2.  An evaluation of factors associated with taking and responding positive to the tuberculin skin test in individuals with HIV/AIDS.

Authors:  Líbia C R V Moura; Ricardo A A Ximenes; Heloísa L Ramos; Demócrito B Miranda Filho; Carolina D P Freitas; Rosangela M S Silva; Isabella Coimbra; Joanna d'Arc L Batista; Ulisses R Montarroyos; Maria de Fátima P Militão Albuquerque
Journal:  BMC Public Health       Date:  2011-09-05       Impact factor: 3.295

3.  Seroprevalence of HCV, HBV and HIV in two inner-city London emergency departments.

Authors:  L Cieply; R Simmons; S Ijaz; E Kara; A Rodger; W Rosenberg; A McGuinness; J L Mbisa; J Ledesma; N Ohemeng-Kumi; S Dicks; H Potts; S Lattimore; S Mandal
Journal:  Epidemiol Infect       Date:  2019-01       Impact factor: 2.451

Review 4.  Communicable respiratory threats in the ED: tuberculosis, influenza, SARS, and other aerosolized infections.

Authors:  Richard E Rothman; Yu-Hsiang Hsieh; Samuel Yang
Journal:  Emerg Med Clin North Am       Date:  2006-11       Impact factor: 2.264

Review 5.  The role of counselling in tuberculosis diagnostic evaluation and contact tracing: scoping review and stakeholder consultation of knowledge and research gaps.

Authors:  Isabel Foster; Amanda Sullivan; Goodman Makanda; Ingrid Schoeman; Phumeza Tisile; Helene-Mari van der Westhuizen; Grant Theron; Ruvandhi R Nathavitharana
Journal:  BMC Public Health       Date:  2022-01-28       Impact factor: 3.295

6.  Screening for tuberculosis among high-risk groups attending London emergency departments: a prospective observational study.

Authors:  Rishi K Gupta; Swaib A Lule; Maria Krutikov; Lara Gosce; Nathan Green; Jo Southern; Ambreen Imran; Robert W Aldridge; Heinke Kunst; Marc Lipman; William Lynn; Helen Burgess; Asif Rahman; Dee Menezes; Ananna Rahman; Simon Tiberi; Peter J White; Ibrahim Abubakar
Journal:  Eur Respir J       Date:  2021-06-24       Impact factor: 16.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.